NUREXONE BIOLOGIC INC. (J90) — Working Capital to Net Assets Ratio
NUREXONE BIOLOGIC INC. (J90) has a Working Capital to Net Assets ratio of 58.4% as of December 2025. Working capital of €1.61 Million (current assets of €2.60 Million minus current liabilities of €989.00K) is measured against net assets of €2.76 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
NUREXONE BIOLOGIC INC. Working Capital to Net Assets (2021–2025)
This chart shows how NUREXONE BIOLOGIC INC.'s Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 58.4%, reflecting working capital of €1.61 Million against net assets of €2.76 Million EUR. For the complete balance sheet picture, see J90 asset base.
Annual Working Capital to Net Assets for NUREXONE BIOLOGIC INC. (2021–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for NUREXONE BIOLOGIC INC. from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read J90 current and long-term liabilities for a breakdown of total debt and financial obligations.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 58.4% | €1.61 Million | €2.76 Million | €2.60 Million | €989.00K | ▼ -11.7 pp |
| 2024 | 70.2% | €1.24 Million | €1.76 Million | €1.63 Million | €398.00K | ▲ +31.0 pp |
| 2023 | 39.2% | €74.00K | €189.00K | €1.98 Million | €1.91 Million | ▼ -60.5 pp |
| 2022 | 99.7% | €2.09 Million | €2.10 Million | €2.69 Million | €603.00K | ▼ -2.7 pp |
| 2021 | 102.4% | €1.21 Million | €1.18 Million | €2.84 Million | €1.63 Million | — |